Literature DB >> 17933567

Visual Analogue Scale to score the effects of Botulinum Toxin A treatment in children with cerebral palsy in daily clinical practice.

Georges F Vles1, Anton J A de Louw, Lucianne A Speth, Lodewijk W van Rhijn, Yvonne J M Janssen-Potten, Jos G Hendriksen, Johan S H Vles.   

Abstract

OBJECTIVE: This study examined the reliability and efficiacy of the Visual Analogue Scale (VAS) in evaluating spasticity treatment in an outpatient setting. PATIENTS AND METHODS: We used a parent-reported VAS device for evaluating the effects of Botulinum Toxin A (BTX-A). Data were collected on 55 children with cerebral palsy. Individual goals of treatment were formulated in close consultation with the caregivers. The categories of treatment options were improvement of pain, problems with nursing, sitting position, standing and walking.
RESULTS: Seventy-four interventions were performed in 55 children. A statistically significant effect was found for improvement of nursing, standing and walking. No statistically significant effect for pain was found, probably because of small numbers. In seven children there was no effect at all. Side effects were observed in five children.
CONCLUSION: In using a VAS instrument, beneficial effects were found for nursing, standing and walking after BTX-A treatment. A positive (not significant) correlation was found between the VAS and the Modified Tardieu for those children who also underwent a gait analysis. Evaluating spasticity treatment with the use of the VAS has an important advantage because it is a quick and easy method for evaluating individually defined treatment goals in an outpatient setting, in which time-consuming evaluations are not an option.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17933567     DOI: 10.1016/j.ejpn.2007.08.002

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  5 in total

1.  Validity of three rating scales for measuring pain intensity in youths with physical disabilities.

Authors:  J Miró; E Castarlenas; R de la Vega; E Solé; C Tomé-Pires; M P Jensen; J M Engel; M Racine
Journal:  Eur J Pain       Date:  2015-03-31       Impact factor: 3.931

2.  Percutaneous radiofrequency lesions adjacent to the dorsal root ganglion alleviate spasticity and pain in children with cerebral palsy: pilot study in 17 patients.

Authors:  Georges F Vles; Johan S Vles; Maarten van Kleef; Jan van Zundert; Heleen M Staal; Wim E Weber; Lodewijk W van Rhijn; Dan Soudant; H Kerr Graham; Anton J de Louw
Journal:  BMC Neurol       Date:  2010-06-22       Impact factor: 2.474

3.  Ultrasound-guided injection of botulinum toxin A in the treatment of iliopsoas spasticity.

Authors:  L M Sconfienza; N Perrone; F Lacelli; C Lentino; G Serafini
Journal:  J Ultrasound       Date:  2008-07-03

Review 4.  Analgesic Effects of Botulinum Toxin in Children with CP.

Authors:  Josephine Sandahl Michelsen; Gitte Normann; Christian Wong
Journal:  Toxins (Basel)       Date:  2018-04-19       Impact factor: 4.546

5.  Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy.

Authors:  Christian Wong; Ian Westphall; Josephine Sandahl Michelsen
Journal:  Toxins (Basel)       Date:  2022-01-05       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.